LXRα
- [1]. Liver X Receptor Alphaet.
- [2]. LXRα gene information from NCBI.
- [3]. Uniprotkb.
- [4]. Lockhart SM, et al. Damaging mutations in liver X receptor-α are hepatotoxic and implicate cholesterol sensing in liver health. Nat Metab. 2024 Oct;6(10):1922-1938. [Content Brief]
- [5]. Wikipedia.
- [6]. Li Y, et al. Induction of human liver X receptor alpha gene expression via an autoregulatory loop mechanism. Mol Endocrinol. 2002 Mar;16(3):506-14. [Content Brief]
- [7]. Whitney KD, et al. Liver X receptor (LXR) regulation of the LXRalpha gene in human macrophages. The Journal of Biological Chemistry. 2001 Nov;276(47):43509-43515. [Content Brief]
-
LXRα Related Products (6)
Related Products (6)
-
22(R)-Hydroxycholesterol
0 ImagesSynonyms: Narthesterol22 (R)-Hydroxycholesterol (Narthesterol) is a natural oxysterol, acting as a LXRα agonist that inhibits cancer cell proliferation. 22 (R)-Hydroxycholesterol activates LXRα-mediated upregulation of downstream ABCA1 expression, enhances apolipoprotein-dependent cholesterol efflux, reduces intracellular cholesterol content, and decreases the production of β-amyloid peptide. 22 (R)-Hydroxycholesterol induces the differentiation of human mesenchymal stem cells into functional dopaminergic neurons. 22 (R)-Hydroxycholesterol is applicable to research related to cancer, Alzheimer's disease, and Parkinson's disease. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
TLC-2716
0 ImagesCat. No.: HY-182014CAS No.: 2408041-54-1TLC-2716 is an orally available, gut- and liver-restricted inhibitor against LXRα and LXRβ, with EC50 values of 7 nM and 15 nM, respectively. TLC-2716 represses LXRα/β transcriptional activity, downregulates genes involved in lipogenesis, lipid absorption and lipoprotein metabolism, and preserves peripheral reverse cholesterol transport. TLC-2716 reduces lipid accumulation, suppresses inflammation and fibrotic gene expression, enhances triglyceride-rich lipoprotein clearance, and improves glucose homeostasis and insulin sensitivity. TLC-2716 lowers serum and hepatic triglycerides, plasma cholesterol and other atherogenic lipid profiles in experimental models and humanized liver mice. TLC-2716 can be used for the research of dyslipidemia and related cardiometabolic disorders. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Ginsenoside C-K hexapropionate ester
0 ImagesGinsenoside C-K hexapropionate ester (Structure 2) is a selective agonist of LXRα, with no significant activation effect on LXRβ. Ginsenoside C-K hexapropionate ester upregulates the expression of downstream genes such as ABCA1 by activating LXRα, promoting reverse cholesterol transport, and reducing lipid deposition in macrophage-derived foam cells. It can be used in the research of atherosclerosis. Ginsenoside C-K hexapropionate ester is a derivative synthesized from ginsenoside Compound K, an active metabolite of Panax notoginseng saponins, by modification with propionic anhydride. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
LXRα agonist 1
0 ImagesCat. No.: HY-173393CAS No.: 1790089-97-2LXRα agonist 1 is a selective LXRα agonist, with EC50 values of 42 nM and 266 nM against purified LXRα and LXRβ, respectively. LXRα agonist 1 acts as a lipotoxicity inducer, triggering the production of toxic saturated fatty acids in tumor cells, and induces lipotoxicity-mediated cancer cell death when combined with the Raf inhibitor Sorafenib (HY-10201). LXRα agonist 1 can be used in the research of hepatocellular carcinoma. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
27-Norcholestenoic acid
0 ImagesCat. No.: HY-160126CAS No.: 2154373-60-927-Norcholestenoic acid is an inverse agonist of LXRβ and LXRα that decreases basal luciferase activity and inhibits agonist-induced transactivation. 27-Norcholestenoic acid induces conformational changes in the AF-2 domain that favor corepressor over coactivator recruitment, thereby destabilizing the active receptor conformation. 27-Norcholestenoic acid downregulates FASN and SREBP-1a/c gene expression. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
-
Gypenoside LVI
0 ImagesCat. No.: HY-N21887CAS No.: 105214-48-0Gypenoside LVI is an orally active dammarane-type triterpenoid compound found in Gynostemma pentaphyllum. Gypenoside LVI inhibits ERK and JNK phosphorylation, the NLRP3 inflammasome, and modulates M1 to M2 microglial polarization. Gypenoside LVI downregulates PCSK9 expression through a SREBP-independent pathway. Gypenoside LVI promotes cholesterol efflux via ABCG1 and SRB1, upregulates LXRα-mediated reverse cholesterol transport, and attenuates foam cell formation by reducing lipid accumulation and cholesterol uptake. Gypenoside LVI inhibits IL-6 and IL-1β secretion, reduces oxidative stress, neuroinflammation, microglial and astrocyte activation, and inhibits LPS-induced microglial proliferation. Gypenoside LVI can be used for research on atherosclerosis, hypercholesterolemia, depression, and non-small cell lung cancer. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -